pSivida Corp. (NASDAQ: PSDV)

pSivida Corp. (NASDAQ: PSDV) has focused their efforts on developing drug delivery products, with an initial focus on ophthalmology and oncology. The company generates revenues through the marketing of the only two FDA approved sustained release back of the eye treatments for chronic eye disease. Substantial revenues are anticipated shortly from their varied late-stage product portfolio that includes a next generation product designed to treat Diabetic Macular Edema as well as other ophthalmic applications. For further information, visit the Company’s web site at www.psivida.com.